Maze Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 |
|---|---|---|
| Revenue | — | $167.5M |
| Operating income | -$142.9M | $57.6M |
| Operating expenses | $142.9M | $109.9M |
| Cash from operations | -$111.9M | $76.0M |
| Capital expenditure | $794,000 | $1.1M |
| Free cash flow | -$112.7M | $74.8M |
| Impairments | $0 | $0 |
| Total assets | $397.1M | $240.5M |
| Total liabilities | $42.2M | $43.6M |
Shares outstanding 55.3M · Free float 85.2%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.